Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

Vergote I; du Bois A.; Floquet A.; Rau J.; Kim J-W; del Campo J. M.; Friedlander M.; Pignata S.; Fujiwara K.; Colombo N.; Mirza M. R.; Monk B. J.; Tsibulak I; Calvert P. M.; Herzog T. J.; Hanker L. C.; Meunier J.; Lee J-Y; Bologna A.; Carrasco-Alfonso M. J.; Harter P.

首页> 外文期刊>Gynecologic Oncology: An International Journal >Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

【24h】

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

机译：以前的总生存结果 - 卵巢16：一期第3期维护Pazopanib对晚期化疗患者进行晚期卵巢癌的女性患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: The AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC).

机译：目的：以前 - 卵巢16学习旨在测试新诊断先进的晚期卵巢癌（AOC）患者在一线化疗后Pazopanib维持的疗效，安全性和耐受性。

著录项

来源
《Gynecologic Oncology: An International Journal》 |2019年第2期|共6页
作者
Vergote I; du Bois A.; Floquet A.; Rau J.; Kim J-W; del Campo J. M.; Friedlander M.; Pignata S.; Fujiwara K.; Colombo N.; Mirza M. R.; Monk B. J.; Tsibulak I; Calvert P. M.; Herzog T. J.; Hanker L. C.; Meunier J.; Lee J-Y; Bologna A.; Carrasco-Alfonso M. J.; Harter P.;
展开▼
作者单位

BGOG Dept Gynaecol Oncol Leuven Belgium;

AGO Dept Gynecol &

Gynecol Oncol Essen Germany;

GINECO Bordeaux France;

AGO Coordinating Ctr Clin Trials Marburg Germany;

KGOG Dept Obstet &

Gynecol Seoul South Korea;

GEICO Barcelona Spain;

UNSW Prince Wales Clin Sch ANZGOG Randwick NSW Australia;

IRCCS Ist Nazl Studio &

Cura Tumori Fdn G Pascale MITO Naples Italy;

JGOG Dept Gynecol Oncol Saitama Japan;

IRCCS European Inst Oncol MaNGO Milan Italy;

Rigshosp NSGO Dept Oncol Copenhagen Denmark;

Californian Consortium Div Gynecol Oncol Phoenix AZ USA;

AGO Austria Dept Gynecol &

Obstet Innsbruck Austria;

Canc Trials Ireland Innovat House Dublin Ireland;

NYGOG Cincinnati OH USA;

AGO Dept Gynecol &

Obstet Campus Lubeck Lubeck Germany;

Hop La Source Serv Oncol Med Ctr Hosp Reg Orleans Orleans France;

Yonsei Univ Inst Womens Life Med Sci Dept Obstet &

Gynecol Coll Med Seoul South Korea;

UO Oncol Med MaNGO Reggio Emilia Italy;

Novartis Pharmaceut E Hanover NJ USA;

AGO Dept Gynecol &

Gynecol Oncol Essen Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Ovarian cancer; Pazopanib; Targeted therapy; Taxane-platinum-based chemotherapy;

机译：卵巢癌;Pazopanib;有针对性的疗法;紫杉烷 - 铂类化疗;

相似文献

外文文献
中文文献
专利

1. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer [J] . Vergote I, du Bois A., Floquet A., Gynecologic Oncology: An International Journal . 2019,第2期

机译：以前的总生存结果 - 卵巢16：一期第3期维护Pazopanib对晚期化疗患者进行晚期卵巢癌的女性患者
2. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy [J] . Friedlander M., Rau J., Lee C. K., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第3期

机译：先进的上皮卵巢癌患者的生活质量（EOC）在卵巢16次试验中随机随机维修Pazopanib或安慰剂。测量维护治疗试验中患者以患者为中心的终点的内容
3. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study [J] . Kim Jae-Weon, Mahner Sven, Wu Ling-Ying, International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2018,第1期

机译：Pazopanib在东亚女性中患有先进的上皮细胞卵巢癌症的培养治疗：来自ovar16和东亚研究的结果
4. Computer extracted features related to the spatialarrangement of tumor-infiltrating lymphocytes predict overall survival in epithelial ovarian cancer receiving adjuvant chemotherapy [C] . Sepideh Azarianpour, Germán Corredor, Kaustav Bera, Conference on Medical Imaging: Digital Pathology . 2020

机译：计算机提取与空间相关的功能肿瘤浸润淋巴细胞的安排预测上皮性卵巢癌接受佐剂化疗的整体存活
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre randomised placebo-controlled Phase II study (KCSG-LU12-07) [O] . Jong-Mu Sun, Ki Hyeong Lee, Bong-Seog Kim, 2018

机译：一线依托泊苷和铂类化学疗法在广泛疾病小细胞肺癌患者中的帕唑帕尼维持治疗：一项多中心随机安慰剂对照的II期研究（KCSG-LU12-07）
7. Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07) [O] . Jong-Mu Sun, Ki Hyeong Lee, Bong-Seog Kim, 2018

机译：Pazopanib在一线依托磷脂和铂化疗后的广泛疾病小细胞肺癌患者中的维持：多期，随机，安慰剂控制第二阶段研究（KCSG-LU12-07）

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

摘要

著录项

相似文献

相关主题

期刊订阅